This is SPARTAN! Apalutamide treatment for nmCRPC

This is SPARTAN! Apalutamide treatment for nmCRPC

VJOncology

2 years
187 Views
Share Report
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
Highly anticipated data from the Phase III SPARTAN study (NCT01946204), which investigated apalutamide for nonmetastatic castration-resistant prostate cancer (nmCRPC), was presented at the 2018 Genitourinary Cancers Symposium, held in San Francisco, CA. In this interesting interview from the meeting, Eric Small, MD, of the UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, discusses the results of the trial. Dr Small highlights the excellent primary and secondary endpoint data, including risk reduction and time to metastasis, as well as results for toxicity. In addition, he covers the doubled-blinded aspect of the study design and how this affected access to abiraterone treatment for patients.
Up Next Autoplay